Episode
How Pharmacogenomics Deliver More Precise Cancer Therapy
- Podcast
- Answers from the Lab
- Published
- Jun 11, 2026
- Duration seconds
- 1252
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/d92c445f
Actions
POST https://stenobird.com/v1/public/podcasts/answers-from-the-lab-870296/episodes/how-pharmacogenomics-deliver-more-precise-cancer-therapy/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/answers-from-the-lab-870296/how-pharmacogenomics-deliver-more-precise-cancer-therapy.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D. , president and CEO of Mayo Clinic Laboratories, to discuss updates on the Protecting Access to Medicare Act (PAMA) and other policy changes affecting clinical diagnostics. Later, Dr. Pritt welcomes Ann Moyer, M.D., Ph.D. , a molecular genetic pathologist at Mayo Clinic and chair of the hereditary genetics practice, to explore how precision therapeutics are improving cancer treatments. PAMA update (00:01): Get the latest on PAMA as the first data collection period begins, including ongoing efforts to advance the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Policy changes influencing diagnostics (04:09) : Learn how evolving reimbursement policies for blood-based cancer screening and a proposed CLIA modernization bill may impact the field. Pharmacogenomic tests improving cancer care (08:14) : Discover how pharmacogenomics are benefiting patients with cancer, the benefits of medication-based testing, and how this field is advancing. Resources CMS: CLFS & PAMA reporting and resources Precision Oncology Therapeutics: Personalized cancer treatment Answers From the Lab: Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D. Answers From the Lab: Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.